Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
IPO Year: 2014
Exchange: NASDAQ
Website: syneoshealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2023 | $30.00 → $28.00 | Neutral → Underweight | JP Morgan |
| 1/17/2023 | $30.00 → $25.00 | Overweight → Underweight | Barclays |
| 1/13/2023 | $25.00 | Overweight → Underweight | Barclays |
| 12/14/2022 | $66.00 → $38.00 | Buy → Neutral | Mizuho |
| 11/7/2022 | $55.00 → $27.00 | Outperform → In-line | Evercore ISI |
| 10/18/2022 | $85.00 → $53.00 | Overweight → Neutral | JP Morgan |
| 9/14/2022 | Buy → Neutral | Guggenheim | |
| 9/7/2022 | $68.00 | Neutral | UBS |
| 5/24/2022 | $81.00 | Buy | Guggenheim |
| 4/25/2022 | $101.00 → $75.00 | Buy → Hold | Jefferies |
15-12G - Syneos Health, Inc. (0001610950) (Filer)
8-K - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
25-NSE - Syneos Health, Inc. (0001610950) (Subject)
8-K - Syneos Health, Inc. (0001610950) (Filer)
8-K - Syneos Health, Inc. (0001610950) (Filer)
8-K - Syneos Health, Inc. (0001610950) (Filer)
JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00
Mizuho downgraded Syneos Health from Buy to Neutral and set a new price target of $38.00 from $66.00 previously
Evercore ISI downgraded Syneos Health from Outperform to In-line and set a new price target of $27.00 from $55.00 previously
JP Morgan downgraded Syneos Health from Overweight to Neutral and set a new price target of $53.00 from $85.00 previously
Guggenheim downgraded Syneos Health from Buy to Neutral
UBS initiated coverage of Syneos Health with a rating of Neutral and set a new price target of $68.00
Guggenheim initiated coverage of Syneos Health with a rating of Buy and set a new price target of $81.00
Jefferies downgraded Syneos Health from Buy to Hold and set a new price target of $75.00 from $101.00 previously
JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MT
Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALSJERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADIC
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
MORRISVILLE, N.C., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced the completion of its acquisition by a consortium of private investment firm affiliates composed of Elliott Investment Management L.P., Patient Square Capital and Veritas Capital. As a result of the transaction, Syneos Health is now a privately held company. With the support of its new private investors, the Company will be poised to further accelerate its transformation, fuel investments in technology that better differentiate its integrated solutions and expand its commitment to better serve cus
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources
MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers. Under Dr. Haring'
MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the "Issuer" or the "Company") and Syneos Health, Inc. ("Syneos Health"), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the "Notes"). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Health (the "Acquisition") by the Issuer and certain of its affiliated entities (such affiliates, together with the Issuer, the "Purchasing Entities") and related refinancings. The Purchasing Entities were newly-f
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing o
● The study marks Click's second active randomized clinical trial testing digital interventions in migraine patients. ● The ReMMiD-C trial will evaluate the efficacy and safety of investigational digital therapeutics for the prevention of episodic migraine in patients 18 years and older receiving Calcitonin Gene-Related Peptide (CGRP) inhibitor therapy. ● Click and Syneos Health have developed a unique approach utilizing digital, decentralized clinical trial solutions to execute the study. Click Therapeutics, Inc. ("Click"), a leader in Digital Therapeutics™ as prescription medical treatments, today announced the launch of its second active randomized clinical trial in migraine, ReMMi
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources
MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers. Under Dr. Haring'
MORRISVILLE, N.C., July 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Hillary Bochniak as Chief Human Resources Officer, effective July 10, 2023. Ms. Bochniak joins Syneos Health from Accenture where she spent nearly 30 years in human resources (HR) roles of increasing scope and responsibility. Most recently, she served as the Managing Director, Global HR Lead for Strategic Accounts and Sales, where she was a driving force behind Accenture's sales transformation. In this role, she collaborated closely with business leadership to reimagine a best-in-class sales professiona
MORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Batisha Anson to the newly created role of Global Head of Patient Diversity and Health Equity. In this role, Anson will advance Syneos Health's goal to improve diverse representation of patient populations to provide more equitable access to therapies and innovative science. She will help inform diversity, equity and inclusion (DE&I) strategies for investigator sites, patient experience, access, launch and more, accelerating efforts to advance patient diversity in clinical trials and commercial programs.
MORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Bonello as Chief Financial Officer, effective July 1, 2023. Stanford (Ben) Rudnick will continue to serve as Interim Chief Financial Officer until that time. Mr. Bonello has more than 30 years of financial leadership experience, including 15 years in the clinical research industry. He most recently served as Chief Financial Officer of Clario, Inc., a clinical trial data collection company, since 2021. From 2008 to 2021, Mr. Bonello held roles of increasing responsibility at Nasdaq-listed PRA Healt
MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Directors. Mr. Klitgaard was previously a member of the Syneos Board from 2017 until May 2022, having resigned due to a personal matter. The Company also announced today that Todd M. Abbrecht is stepping down from its Board of Directors. "We are excited to welcome Bill back to the Syneos Health Board," said John Dineen, Chair of the Syneos Health Board of Directors. "Bill's deep financial expertise combined with his knowledge of our company are a welcome addition to an
MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. "We are excited to welcome Barbara and Alfonso to the Syneos Health Board," said John Dineen, Chair of the Syneos Health Board of Directors. "Barbara's deep financial expertise combined with Alfonso's expansive industry knowledge and international experience bring important perspectives to an already strong Board. These two leaders will enhance the composition of our Board and support continued successful overs
MORRISVILLE, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Brooks to the newly created role of Chief Development Officer. In this role, Brooks will help drive Syneos Health's growth strategy, building a broader, proactive go-to-market ecosystem. Leading the company's Customer Engagement and Market Development portfolio, he'll advance innovation and the voice of the customer across the product development continuum to create better outcomes for patients worldwide. "COVID-19 has forever changed the way we work with customers and colleagues, and how we effe
MORRISVILLE, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of David S. Wilkes, M.D., to the Company's Board of Directors. "We are thrilled to welcome Dr. Wilkes to the Syneos Health Board," said John Dineen, Chairman of the Syneos Health Board of Directors. "He is a distinguished medical expert with years of experience in academic, research-driven, entrepreneurial and public company settings. Dr. Wilkes shares our passion for positively impacting the lives of patients and is a champion for addressing health disparities. We are truly fortunate to have the opportunity
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13D/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13D/A - Syneos Health, Inc. (0001610950) (Subject)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing o
Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management ("Elliott"), Patient Square Capital ("Patient Square"), and Veritas Capital ("Veritas") for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a
MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uni
Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $470.1 million for the fourth quarter, year-over-year growth of 31.2% and a book-to-bill ratio of 0.46x, and $2,841.6 million for the trailing twelve months, a year-over-year decline of 35.0% and a book-to-bill ratio of 0.70x.Excluding reimbursable out-of-pocket expenses, $268.9 million for the fourth quarter, a year-over-year decline of 70.0% and a book-to-bill ratio of 0.39x, and $2,148.5 million for the trailing twelve months, a
MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a
Revenue for the third quarter of $1,336.2 million decreased 0.9% on a reported basis and increased 2.2% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $182.2 million for the third quarter, a year-over-year decline of 86.5% and a book-to-bill ratio of 0.18x, and $2,729.7 million for the trailing twelve months, a year-over-year decline of 48.8% and a book-to-bill ratio of 0.67x.Excluding reimbursable out-of-pocket expenses, $208.4 million for the third quarter, a year-over-year decline of 80.0% and a book-to-bill ratio of 0.30x, and $2,776.1 million for the trailing twelve months, a
MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode an
Revenue for the second quarter of $1,360.7 million increased 6.1% on a reported basis and 8.3% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $947.4 million for the second quarter, a year-over-year decline of 34.2% and a book-to-bill ratio of 0.92x, and $3,901.5 million for the trailing twelve months, a year-over-year decline of 21.7% and a book-to-bill ratio of 0.94x.Excluding reimbursable out-of-pocket expenses, $758.5 million for the second quarter, a year-over-year decline of 15.1% and a book-to-bill ratio of 1.06x, and $3,608.6 million for the trailing twelve months, year-ov
MORRISVILLE, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2022 financial results on Tuesday, August 2, 2022, prior to its earnings call at 9:00 a.m. ET. Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID
Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles Michael Brooks Named Chief Operating Officer Company Reports First Quarter 2022 Results and Updates Full Year Guidance MORRISVILLE, N.C., April 29, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michelle Keefe as CEO and a member of the Company's Board of Directors. Keefe, currently President, Medical Affairs and Commercial Solutions, succeeds Alistair Macdonald, who will retire after 20 years at Syneos Health. Macdonald will remain an advisor to Syneos Health through March 2023. Keefe brings more than